A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Study was stopped following a strategic decision from the Sponsor. It was not based on any safety findings or safety concerns with sabatolimab.

Conditions

Myelodysplastic Syndrome (MDS)

Interventions

DRUG: sabatolimab
DRUG: azacitidine
DRUG: venetoclax

Sponsor

Novartis Pharmaceuticals